Evidence map›Paper›PMID 36404550›Full record

ArticleJournal of Alzheimer's disease : JAD2023

Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.

Neal R Swerdlow, Yash B Joshi, Joyce Sprock, Jo Talledo, Juan L Molina, Lisa Delano-Wood, Dylan Iwanaga, Juliana E Kotz, Steven Huege, Gabriel C Léger and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Neal R SwerdlowDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Yash B JoshiDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Joyce SprockDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jo TalledoDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Juan L MolinaDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Lisa Delano-WoodDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Dylan IwanagaDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Juliana E KotzDepartment of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, CA, USA.
Steven HuegeDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Gabriel C LégerDepartment of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Gregory A LightDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
University of California, San Diego · USMental Illness Research, Education and Clinical Centers · USVA San Diego Healthcare System · USUniversity of California, Los Angeles · US

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mark W Bondi · 2019 to 2026
$34.9M
Biomarker Predictors of Memantine Sensitivity in patients with Alzheimer's DiseaseR01AG059640 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 2018 to 2022
$2.0M
NIA NIH HHS P30 AG062429NIA NIH HHS R01 AG059640RRD VA IK1 RX003683RRD VA IK2 RX003395
6 · The paper itself

Abstract

backgroundThe uncompetitive NMDA antagonist, memantine (MEM), enhances prepulse inhibition of startle (PPI) across species. MEM is used to treat Alzheimer's disease (AD); conceivably, its acute impact on PPI might be used to predict a patient's sensitivity to MEM's therapeutic effects.

objectiveTo begin to test this possibility, we studied MEM effects on PPI and related measures in AD patients.

methods18 carefully screened individuals with AD (mean age = 72.8 y; M:F=9 : 9) completed double-blind order-balanced testing with MEM (placebo versus 20 mg), assessing acoustic startle magnitude, habituation, PPI, and latency.

resultsFifteen out of 18 participants exhibited reliable startle responses. MEM did not significantly impact startle magnitude or habituation. Compared to placebo responses, PPI was significantly increased after MEM (p < 0.04; d = 0.40); this comparison reached a large effect size for the 60 ms interval (d = 0.62), where maximal MEM effects on PPI were previously detected. Prepulses reduced peak startle latency ("latency facilitation") and this effect was amplified after MEM (p = 0.03; d = 0.41; for 60 ms intervals, d = 0.69). No effects of MEM were detected on cognition, nor were MEM effects on startle associated with cognitive or clinical measures.

conclusionMEM enhances prepulse effects on startle magnitude and latency in AD; these changes in PPI and latency facilitation with MEM suggest that these measures can be used to detect an AD patient's neural sensitivity to acute MEM challenge. Studies in progress will determine whether such a "biomarker" measured at the outset on treatment can predict sensitivity to MEM's therapeutic effects.

Indexed as

Alzheimer DiseaseMemantineAcoustic StimulationAgedCognitionDouble-Blind MethodFemaleHumansMaleReflex, StartleMemantineAlzheimer’s diseasememantineneurocognitionprepulse inhibition

Identifiers

PMID36404550
PMCPMC12416332
OpenAlexW4309455864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.